Trial Profile
EFFICACY AND SAFETY OF BONE MARROW-DERIVED MESENCHYMAL CARDIOPOIETIC CELLS (C3BS-CQR-1) FOR THE TREATMENT OF CHRONIC ISCHEMIC HEART FAILURE
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs C3BS CQR 1 (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms CHART-2
- Sponsors Celyad Oncology
- 18 Nov 2019 Results presented at the American Heart Association Scientific Sessions 2019.
- 07 Jul 2016 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2017.
- 07 Jul 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.